An agile and patented advanced pharmaceutical manufacturing technology paving the way for rapid, low-cost and scalable domestic API production.
Bright Path Labs (BPL) is positioned to immediately fill gaps in the drug supply chain in response to the COVID-19 pandemic; including the agile manufacturing of hydroxychloroquine (HCQ), and other potential treatments or subsequently discovered vaccines and medicines to address future health challenges.
We have the physical and technical capacity for the agile research and development of advanced pharmaceutical manufacturing that is scalable, that helps us train a future workforce for research and is able to support Federal agencies to rapidly address drug shortages.